LEXINGTON, Mass.—BioScale, Inc., a life science company marketing a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products, today announced the appointment of Riccardo Pigliucci to its Board of Directors.

Riccardo is an influential leader in the executive ranks of the global analytical tools industry. For more than 30 years, he has guided private and publicly-listed high technology companies. Riccardo brings a wide range of experience in sales, marketing, operations, financing, acquisitions and public offerings within the life science, biotechnology and pharmaceutical space. He is a former President, COO, and Board Member of The Perkin Elmer Corporation, and also served as CEO of Life Sciences International plc. He was CEO of Discovery Partners International and led this company through a successful IPO. Most recently, Riccardo was the Lead Director on the Board of Dionex, a public company recently purchased by Thermo Fisher for more than $2B.

Mark Lundstrom, BioScale Founder and CEO, commented, “It is an honor to add an accomplished and recognized leader like Riccardo Pigliucci to our Board of Directors. We welcome his in-depth experience, impressive professional network and successful track record as we enter a phase of rapid growth in building BioScale’s commercial infrastructure following the launch of our ViBE™ protein analysis platform. We look forward to his active involvement and support as a Director and believe he can have an immediate impact on our vision and business initiatives.”

“I am pleased to be joining the BioScale Board at such a pivotal time in the organization’s development,” said Mr. Pigliucci. “The Company is poised to make substantial contributions to protein research. Its cutting edge technology is a scientific breakthrough which has the ability to change the paradigm for protein measurement across the drug development and diagnostic industries. I am delighted to be working with the BioScale leadership team as they move through the successful commercialization of this powerful technology.”

Riccardo replaces Dr. Paul Billings who is leaving the BioScale Board after five years of service. “BioScale is grateful to Dr. Billings for his dedication and guidance,” commented Mark Lundstrom. “Paul recently joined LIFE Technologies as their Chief Medical Officer and we wish him much success in his new role. We are also pleased to announce that Paul has agreed to transition to Chair our Scientific Advisory Board.”

About BioScale, Inc.

BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE™ platform powered by its AMMP™ (Acoustic Membrane Microparticle) technology enables highly-sensitive detection and quantitation of proteins in complex samples used in pre-clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. BioScale is headquartered in Lexington, MA. For more information, visit www.bioscale.com.